InforMatrix for attention deficit hyperactivity disorder

Janknegt, Robert; Faber, Adrianne; Pereira, Rob Rodrigues; Kalverdijk, Luuk J.

doi:10.1517/14656560902765769

Cited by 1 publication

(1 citation statement)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Psychopharmacological agents affecting catecholaminergic and α-2-adrenergic transmission continue to figure prominently in ADHD treatment [24,25]. Over the past 3 years, however, more attention has been paid to prescribing patterns [26-28], matching medication with patient characteristics [29], and factors that promote treatment adherence in pediatric [30-35] and young adult populations [36]. In the following section, current treatment options for both adults and children with ADHD will be discussed.…”

Section: Introductionmentioning

confidence: 99%

Advances in understanding and treating ADHD

Antshel

Hargrave

Simonescu

et al. 2011

BMC Med

109

View full text Add to dashboard Cite

Attention deficit hyperactivity disorder (ADHD) is a neurocognitive behavioral developmental disorder most commonly seen in childhood and adolescence, which often extends to the adult years. Relative to a decade ago, there has been extensive research into understanding the factors underlying ADHD, leading to far more treatment options available for both adolescents and adults with this disorder. Novel stimulant formulations have made it possible to tailor treatment to the duration of efficacy required by patients, and to help mitigate the potential for abuse, misuse and diversion. Several new non-stimulant options have also emerged in the past few years. Among these, cognitive behavioral interventions have proven popular in the treatment of adult ADHD, especially within the adult population who cannot or will not use medications, along with the many medication-treated patients who continue to show residual disability.

show abstract